[67Cu]Cu-NOTA-trastuzumab

[67Cu]Cu-NOTA-trastuzumab is an investigational **radiopharmaceutical** and **radiolabeled monoclonal antibody** composed of trastuzumab conjugated to the chelator p-SCN-Bn-NOTA and labeled with the therapeutic radioisotope copper-67. The agent is designed for **HER2-positive breast cancer** as a **radioimmunotheranostic**: trastuzumab directs the conjugate to **human epidermal growth factor receptor 2**, enabling HER2-selective tumor localization, while the copper-67 payload provides cytotoxic radiation and can also support imaging-oriented theranostic evaluation. Based on the provided preclinical literature context, the program appears to be in **preclinical or research-stage academic development**, with reported xenograft activity exceeding unlabeled trastuzumab in HER2-positive breast cancer models including BT-474 and JIMT-1.

Other names

67Cu-NOTA-trastuzumabcopper-67 NOTA-trastuzumabcopper67 NOTA-trastuzumabcopper 67 NOTA-trastuzumab[67Cu]Cu-p-SCN-Bn-NOTA-trastuzumab